Indeed, at this time, we are aware of no evidence that the practice of authorized generics has actually deterred any Paragraph IV certification or post-180 day generic entry, let alone a challenge to an invalid patent.
How Digital Medicine Can Pinpoint Dosing Regimens to Optimize Drug Efficacy and Safety
Sponsored By Oracle
Multi-faceted Approaches to Meet Payer and Regulatory Evidence Requirements
Sponsored By UBC Express Scripts
Overcoming the Life Sciences Content Conundrum in a Multichannel World
Sponsored By Veeva